• Publications
  • Influence
Clonal evolution of glioblastoma under therapy
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. To better understand how GBM evolves, we analyzed longitudinal genomic and transcriptomic data from 114 patients. TheExpand
  • 269
  • 25
Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas
A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential. These findings raise an attractive hypothesis thatExpand
  • 306
  • 14
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
BACKGROUND Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combinationExpand
  • 511
  • 10
Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells
BackgroundIntra-tumoral genetic and functional heterogeneity correlates with cancer clinical prognoses. However, the mechanisms by which intra-tumoral heterogeneity impacts therapeutic outcome remainExpand
  • 154
  • 8
MET signaling regulates glioblastoma stem cells.
Glioblastomas multiforme (GBM) contain highly tumorigenic, self-renewing populations of stem/initiating cells [glioblastoma stem cells (GSC)] that contribute to tumor propagation and treatmentExpand
  • 125
  • 8
Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles.
Nanometer-sized colloidal particles (nanoparticles) have been extensively used in biomedical applications as a result of their many useful electronic, optical, and magnetic properties that areExpand
  • 477
  • 7
WNT signaling in glioblastoma and therapeutic opportunities
WNTs and their downstream effectors regulate proliferation, death, and migration and cell fate decision. Deregulation of WNT signaling is associated with various cancers including GBM, which is theExpand
  • 102
  • 7
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are critical for improvedExpand
  • 135
  • 5
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ.
Frequent discrepancies between preclinical and clinical results of anticancer agents demand a reliable translational platform that can precisely recapitulate the biology of human cancers. AnotherExpand
  • 133
  • 5
Primary Central Nervous System Lymphoma in Korea: Comparison of B- and T-cell Lymphomas
  • J. Choi, D. Nam, +4 authors H. Ree
  • Medicine
  • The American journal of surgical pathology
  • 1 July 2003
The great majority of primary central nervous system lymphoma (PCNSL) is known to be of B-lineage, with T-cell PCNSL (T-PCNSL) accounting for <5%. We report an unusually high incidence of T-cellExpand
  • 52
  • 5